HOXA5  ||| S:0 E:6 ||| NNP
indicates  ||| S:6 E:16 ||| VBZ
poor  ||| S:16 E:21 ||| JJ
prognosis  ||| S:21 E:31 ||| NN
and  ||| S:31 E:35 ||| CC
suppresses  ||| S:35 E:46 ||| JJ
cell  ||| S:46 E:51 ||| NN
proliferation  ||| S:51 E:65 ||| NN
by  ||| S:65 E:68 ||| IN
regulating  ||| S:68 E:79 ||| VBG
p21  ||| S:79 E:83 ||| CD
expression  ||| S:83 E:94 ||| NN
in  ||| S:94 E:97 ||| IN
non  ||| S:97 E:101 ||| JJ
small  ||| S:101 E:107 ||| JJ
cell  ||| S:107 E:112 ||| NN
lung  ||| S:112 E:117 ||| NN
cancer  ||| S:117 E:124 ||| NN
Homeobox  ||| S:124 E:133 ||| NNP
genes ||| S:133 E:138 ||| NNS
,  ||| S:138 E:140 ||| ,
a  ||| S:140 E:142 ||| DT
superfamily  ||| S:142 E:154 ||| NN
of  ||| S:154 E:157 ||| IN
evolutionarily  ||| S:157 E:172 ||| JJ
conserved  ||| S:172 E:182 ||| JJ
developmental  ||| S:182 E:196 ||| JJ
genes ||| S:196 E:201 ||| NNS
,  ||| S:201 E:203 ||| ,
function  ||| S:203 E:212 ||| NN
as  ||| S:212 E:215 ||| IN
critical  ||| S:215 E:224 ||| JJ
master  ||| S:224 E:231 ||| NN
regulatory  ||| S:231 E:242 ||| JJ
factors  ||| S:242 E:250 ||| NNS
in  ||| S:250 E:253 ||| IN
controlling  ||| S:253 E:265 ||| VBG
body  ||| S:265 E:270 ||| NN
plan  ||| S:270 E:275 ||| NN
specification  ||| S:275 E:289 ||| NNS
and  ||| S:289 E:293 ||| CC
cell  ||| S:293 E:298 ||| NN
fate  ||| S:298 E:303 ||| NN
determination ||| S:303 E:316 ||| NN
.  ||| S:316 E:318 ||| .
Recently ||| S:318 E:326 ||| RB
,  ||| S:326 E:328 ||| ,
a  ||| S:328 E:330 ||| DT
substantial  ||| S:330 E:342 ||| JJ
body  ||| S:342 E:347 ||| NN
of  ||| S:347 E:350 ||| IN
evidence  ||| S:350 E:359 ||| NN
indicates  ||| S:359 E:369 ||| VBZ
that  ||| S:369 E:374 ||| IN
the  ||| S:374 E:378 ||| DT
aberrant  ||| S:378 E:387 ||| JJ
Homeobox  ||| S:387 E:396 ||| NNP
( ||| S:396 E:397 ||| -LRB-
HOX ||| S:397 E:400 ||| NNP
)  ||| S:400 E:402 ||| -RRB-
genes  ||| S:402 E:408 ||| NNS
also  ||| S:408 E:413 ||| RB
play  ||| S:413 E:418 ||| VB
key  ||| S:418 E:422 ||| JJ
roles  ||| S:422 E:428 ||| NNS
in  ||| S:428 E:431 ||| IN
the  ||| S:431 E:435 ||| DT
development  ||| S:435 E:447 ||| NN
of  ||| S:447 E:450 ||| IN
cancers ||| S:450 E:457 ||| NNS
.  ||| S:457 E:459 ||| .
Many  ||| S:459 E:464 ||| JJ
reports  ||| S:464 E:472 ||| NNS
have  ||| S:472 E:477 ||| VBP
shown  ||| S:477 E:483 ||| VBN
not  ||| S:483 E:487 ||| RB
only  ||| S:487 E:492 ||| RB
that  ||| S:492 E:497 ||| IN
HOX  ||| S:497 E:501 ||| NNP
gene  ||| S:501 E:506 ||| NN
expression  ||| S:506 E:517 ||| NN
is  ||| S:517 E:520 ||| VBZ
upregulated  ||| S:520 E:532 ||| VBN
or  ||| S:532 E:535 ||| CC
downregulated  ||| S:535 E:549 ||| NN
in  ||| S:549 E:552 ||| IN
many  ||| S:552 E:557 ||| JJ
cancers  ||| S:557 E:565 ||| NNS
but  ||| S:565 E:569 ||| CC
also  ||| S:569 E:574 ||| RB
that  ||| S:574 E:579 ||| IN
the  ||| S:579 E:583 ||| DT
expression  ||| S:583 E:594 ||| NN
of  ||| S:594 E:597 ||| IN
specific  ||| S:597 E:606 ||| JJ
HOX  ||| S:606 E:610 ||| NN
genes  ||| S:610 E:616 ||| NNS
tends  ||| S:616 E:622 ||| VBZ
to  ||| S:622 E:625 ||| TO
differ  ||| S:625 E:632 ||| VB
based  ||| S:632 E:638 ||| VBN
on  ||| S:638 E:641 ||| IN
tissue  ||| S:641 E:648 ||| NN
type ||| S:648 E:652 ||| NN
.  ||| S:652 E:654 ||| .
Homeobox  ||| S:654 E:663 ||| NNP
A5  ||| S:663 E:666 ||| NNP
( ||| S:666 E:667 ||| -LRB-
HOXA5 ||| S:667 E:672 ||| NNP
)  ||| S:672 E:674 ||| -RRB-
is  ||| S:674 E:677 ||| VBZ
a  ||| S:677 E:679 ||| DT
master  ||| S:679 E:686 ||| NN
regulator  ||| S:686 E:696 ||| NN
of  ||| S:696 E:699 ||| IN
the  ||| S:699 E:703 ||| DT
morphogenesis  ||| S:703 E:717 ||| NN
and  ||| S:717 E:721 ||| CC
cell  ||| S:721 E:726 ||| NN
differentiation ||| S:726 E:741 ||| NN
,  ||| S:741 E:743 ||| ,
and  ||| S:743 E:747 ||| CC
its  ||| S:747 E:751 ||| PRP$
expression  ||| S:751 E:762 ||| NN
is  ||| S:762 E:765 ||| VBZ
also  ||| S:765 E:770 ||| RB
downregulated  ||| S:770 E:784 ||| VBN
in  ||| S:784 E:787 ||| IN
many  ||| S:787 E:792 ||| JJ
cancers  ||| S:792 E:800 ||| NNS
mediated  ||| S:800 E:809 ||| VBN
by  ||| S:809 E:812 ||| IN
DNA  ||| S:812 E:816 ||| NNP
methylation ||| S:816 E:827 ||| NN
.  ||| S:827 E:829 ||| .
However ||| S:829 E:836 ||| RB
,  ||| S:836 E:838 ||| ,
its  ||| S:838 E:842 ||| PRP$
biological  ||| S:842 E:853 ||| JJ
role  ||| S:853 E:858 ||| NN
and  ||| S:858 E:862 ||| CC
clinical  ||| S:862 E:871 ||| JJ
significance  ||| S:871 E:884 ||| NN
in  ||| S:884 E:887 ||| IN
nonsmall  ||| S:887 E:896 ||| JJ
cell  ||| S:896 E:901 ||| NN
lung  ||| S:901 E:906 ||| NN
cancer  ||| S:906 E:913 ||| NN
( ||| S:913 E:914 ||| -LRB-
NSCLC ||| S:914 E:919 ||| NNP
)  ||| S:919 E:921 ||| -RRB-
development  ||| S:921 E:933 ||| NN
and  ||| S:933 E:937 ||| CC
progression  ||| S:937 E:949 ||| NNS
are  ||| S:949 E:953 ||| VBP
not  ||| S:953 E:957 ||| RB
well  ||| S:957 E:962 ||| RB
documented ||| S:962 E:972 ||| VBN
.  ||| S:972 E:974 ||| .
In  ||| S:974 E:977 ||| IN
this  ||| S:977 E:982 ||| DT
study ||| S:982 E:987 ||| NN
,  ||| S:987 E:989 ||| ,
we  ||| S:989 E:992 ||| PRP
found  ||| S:992 E:998 ||| VBD
that  ||| S:998 E:1003 ||| DT
expression  ||| S:1003 E:1014 ||| NN
levels  ||| S:1014 E:1021 ||| NNS
of  ||| S:1021 E:1024 ||| IN
HOXA5  ||| S:1024 E:1030 ||| NNP
were  ||| S:1030 E:1035 ||| VBD
significantly  ||| S:1035 E:1049 ||| RB
decreased  ||| S:1049 E:1059 ||| VBN
in  ||| S:1059 E:1062 ||| IN
NSCLC  ||| S:1062 E:1068 ||| NNP
tissues  ||| S:1068 E:1076 ||| NNS
compared  ||| S:1076 E:1085 ||| VBN
with  ||| S:1085 E:1090 ||| IN
adjacent  ||| S:1090 E:1099 ||| JJ
normal  ||| S:1099 E:1106 ||| JJ
tissues ||| S:1106 E:1113 ||| NNS
.  ||| S:1113 E:1115 ||| .
Its  ||| S:1115 E:1119 ||| PRP$
expression  ||| S:1119 E:1130 ||| NN
level  ||| S:1130 E:1136 ||| NN
was  ||| S:1136 E:1140 ||| VBD
significantly  ||| S:1140 E:1154 ||| RB
correlated  ||| S:1154 E:1165 ||| VBN
with  ||| S:1165 E:1170 ||| IN
tumor-node-metastasis  ||| S:1170 E:1192 ||| NNP
( ||| S:1192 E:1193 ||| -LRB-
TNM ||| S:1193 E:1196 ||| NNP
)  ||| S:1196 E:1198 ||| -RRB-
stages ||| S:1198 E:1204 ||| NNS
,  ||| S:1204 E:1206 ||| ,
tumor  ||| S:1206 E:1212 ||| NN
size ||| S:1212 E:1216 ||| NN
,  ||| S:1216 E:1218 ||| ,
and  ||| S:1218 E:1222 ||| CC
lymph  ||| S:1222 E:1228 ||| JJ
node  ||| S:1228 E:1233 ||| JJ
metastasis ||| S:1233 E:1243 ||| NN
.  ||| S:1243 E:1245 ||| .
Moreover ||| S:1245 E:1253 ||| RB
,  ||| S:1253 E:1255 ||| ,
patients  ||| S:1255 E:1264 ||| NNS
with  ||| S:1264 E:1269 ||| IN
lower  ||| S:1269 E:1275 ||| JJR
levels  ||| S:1275 E:1282 ||| NNS
of  ||| S:1282 E:1285 ||| IN
HOXA5  ||| S:1285 E:1291 ||| CD
expression  ||| S:1291 E:1302 ||| NN
had  ||| S:1302 E:1306 ||| VBD
a  ||| S:1306 E:1308 ||| DT
relatively  ||| S:1308 E:1319 ||| RB
poor  ||| S:1319 E:1324 ||| JJ
prognosis ||| S:1324 E:1333 ||| NN
.  ||| S:1333 E:1335 ||| .
Furthermore ||| S:1335 E:1346 ||| RB
,  ||| S:1346 E:1348 ||| ,
ectopic  ||| S:1348 E:1356 ||| JJ
overexpression  ||| S:1356 E:1371 ||| NN
of  ||| S:1371 E:1374 ||| IN
HOXA5  ||| S:1374 E:1380 ||| NNP
could  ||| S:1380 E:1386 ||| MD
inhibit  ||| S:1386 E:1394 ||| VB
cell  ||| S:1394 E:1399 ||| NN
proliferation  ||| S:1399 E:1413 ||| NN
and  ||| S:1413 E:1417 ||| CC
invasion ||| S:1417 E:1425 ||| NN
,  ||| S:1425 E:1427 ||| ,
while  ||| S:1427 E:1433 ||| IN
knockdown  ||| S:1433 E:1443 ||| JJ
HOXA5  ||| S:1443 E:1449 ||| NN
by  ||| S:1449 E:1452 ||| IN
siRNA  ||| S:1452 E:1458 ||| JJ
promoted  ||| S:1458 E:1467 ||| JJ
cell  ||| S:1467 E:1472 ||| NN
proliferation  ||| S:1472 E:1486 ||| NN
in  ||| S:1486 E:1489 ||| IN
NSCLC  ||| S:1489 E:1495 ||| NNP
cells  ||| S:1495 E:1501 ||| NNS
partly  ||| S:1501 E:1508 ||| RB
via  ||| S:1508 E:1512 ||| IN
regulating  ||| S:1512 E:1523 ||| VBG
p21  ||| S:1523 E:1527 ||| CD
expression ||| S:1527 E:1537 ||| NN
.  ||| S:1537 E:1539 ||| .
Our  ||| S:1539 E:1543 ||| PRP$
findings  ||| S:1543 E:1552 ||| NNS
present  ||| S:1552 E:1560 ||| NN
that  ||| S:1560 E:1565 ||| WDT
decreased  ||| S:1565 E:1575 ||| VBD
HOXA5  ||| S:1575 E:1581 ||| NNP
could  ||| S:1581 E:1587 ||| MD
be  ||| S:1587 E:1590 ||| VB
identified  ||| S:1590 E:1601 ||| VBN
as  ||| S:1601 E:1604 ||| IN
a  ||| S:1604 E:1606 ||| DT
poor  ||| S:1606 E:1611 ||| JJ
prognostic  ||| S:1611 E:1622 ||| JJ
biomarker  ||| S:1622 E:1632 ||| NN
in  ||| S:1632 E:1635 ||| IN
NSCLC  ||| S:1635 E:1641 ||| NNP
and  ||| S:1641 E:1645 ||| CC
regulate  ||| S:1645 E:1654 ||| VB
cell  ||| S:1654 E:1659 ||| NN
proliferation  ||| S:1659 E:1673 ||| NN
and  ||| S:1673 E:1677 ||| CC
invasion ||| S:1677 E:1685 ||| NN
.  ||| S:1685 E:1687 ||| .
